Eli Lilly and Co has been granted a patent for MAPT RNAi agents that can reduce MAPT expression and treat tauopathy. The agents consist of specific sequences and modified nucleotides for enhanced efficacy. GlobalData’s report on Eli Lilly and Co gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eli Lilly and Co - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eli Lilly and Co, Cancer treatment biomarkers was a key innovation area identified from patents. Eli Lilly and Co's grant share as of February 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11926827B2) discloses a MAPT RNAi agent with specific characteristics aimed at gene silencing. The agent consists of a sense strand and an antisense strand forming a duplex, with the sense strand containing SEQ ID NO:15 and the antisense strand containing SEQ ID NO:16. Additionally, the nucleotides in both strands can be modified, with options including 2'-fluoro, 2'-O-methyl, or 2'-O—C16 alkyl modified nucleotides. The patent also covers variations in the positioning and types of modified nucleotides in both strands, enhancing the specificity and efficacy of the RNAi agent.

Furthermore, the patent includes claims related to the presence of modified internucleotide linkages, such as phosphorothioate linkages, in the sense and antisense strands. The patent also extends to pharmaceutical compositions containing the MAPT RNAi agent along with a pharmaceutically acceptable carrier. The compositions are designed to target specific nucleic acid sequences, as outlined in the patent, to potentially treat conditions associated with the MAPT gene. Overall, the patent provides a detailed framework for the development and application of RNAi agents targeting MAPT, offering potential therapeutic avenues for related disorders.

To know more about GlobalData’s detailed insights on Eli Lilly and Co, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies